Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Nanosphere Test for Gram-positive Bacteria

NEW YORK (GenomeWeb News) – Nanosphere today said that it has received de novo clearance from the US Food and Drug Administration to market its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on its Verigene System.

The test detects the genus and species for a broad panel of clinically significant gram-positive bacteria, as well as several markers of antimicrobial resistance, including the mecA, vanA, and vanB genes, which confer resistance to methicillin/oxacillin and vancomycin, Nanosphere said. It added that the test can identify bacterial and antimicrobial resistance genes from gram-positive blood culture bottles within two-and-a-half hours, compared to the two to three days required by current microbiological methods.

The sample-to-result BC-GP test automates bacterial DNA extraction and target detection on the Verigene system.

"With the BC-GP test, patients suspected of deadly infections can now get a first-ever diagnostic tool for detecting disease-causing bacteria while simultaneously determining antibiotic resistance within the critical timeframe for making and adjusting initial treatment," Nanosphere CEO William Moffitt said in a statement.

The Northbrook, Ill.-based company added that it is developing a test for gram-negative blood cultures that will detect genus, species, and resistance on an automated platform. It also plans to submit a test for C. difficile and a panel of enteric bacterial and viral pathogens for FDA clearance this year.

Shares of Nanosphere closed up 21 percent at $2.32 in Wednesday trade on the Nasdaq.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.